Life is Sacred. FDA Bureaucracy Is Not. Stop Abortion Pills Now

This month, the pro-life movement will gather in Washington for the annual March for Life, the largest gathering of citizens in America committed to defending the dignity of every human life. These are the same grassroots voices, families, churches, and volunteers who helped build the movement that returned pro-life leadership to the White House and helped elect President Trump. They come to remind our nation that moral courage still matters in public life and that leadership must ultimately be measured by whether it protects the most vulnerable among us.

Yet while President Trump has been a steadfast ally in the defense of life, key members of his administration have unfortunately been either indifferent to that mission or, in some cases, openly hostile to it. Top officials within the Food and Drug Administration (FDA), for example, are working directly against the President’s stated priorities and creating a culture at the agency that devalues life by facilitating the destruction of the unborn and denying hope to the sick and vulnerable.

Nowhere is this clearer than in the FDA’s handling of abortion drugs and life-saving medicines.

Despite being one year into the Trump administration, FDA leadership has still not delivered a promised safety review of mifepristone, despite mounting evidence of complications and growing concern from physicians and women’s health advocates. Even worse, the agency has continued Biden-era policies that expanded access to mifepristone through mail-order distribution and telehealth prescriptions, and even recently approved an additional generic version of the drug. Each of these steps places women at increased risk and stands in direct tension with a pro-life agenda that values both mother and child.

HELP LIFENEWS SAVE BABIES FROM ABORTION! Please help LifeNews.com with a donation!

Likewise, FDA leadership has turned a blind eye to the President’s call for faster access to give patients — including children suffering from debilitating diseases and families facing devastating diagnoses — access to promising therapies under right-to-try policies when conventional options have been exhausted. In fact, under current FDA leadership, the agency has sharply curtailed access to these breakthrough drugs over technical or procedural issues rather than fundamental safety concerns, placing bureaucratic preferences ahead of urgent human need.

Consider the FDA rejection of Ultragenyx’s UX111 on technical manufacturing grounds, despite strong clinical evidence that the therapy was safe and represented one of the only promising treatments for a fatal neurodegenerative disorder. Or its decision to halt the distribution of Sarepta’s Elevidys, the only approved gene therapy for Duchenne muscular dystrophy, amid regulatory disputes over trial data and risk interpretation. The resulting uncertainty left families grappling with these rare childhood diseases confused, frightened, and caught between shifting regulatory judgments and an ailment that does not wait for bureaucratic resolution.

It is time to confront a stark reality. The FDA’s broken bureaucracy has created a devastating paradox: the agency erects formidable barriers that prevent patients from accessing experimental treatments that might save their lives, while simultaneously expanding access to chemical abortion pills that deliberately end life. An administration truly committed to the sanctity of life cannot tolerate a regulatory culture that sends such a contradictory moral signal.

President Trump must therefore take decisive action to reform the FDA. He should start by removing officials like Vinay Prasad, who exercises significant influence over policy at the agency as the Center for Biologics Evaluation and Research (CBER) Director and Chief Medical and Scientific Officer. Prasad’s openly progressive worldview — including public support for abortion rights and his dismissiveness toward right-to-try reforms — reflects a fundamentally different understanding of the value of human life.

Where conservatives see urgency in giving families every possible chance to fight for survival, Prasad’s approach reflects a clinical detachment that elevates process over people and treats patient suffering as an acceptable cost of governance. That same mindset has taken root across layers of left-leaning FDA middle management, reinforcing a culture resistant to reform that may soon require an even more comprehensive reset of obstructionist officials and even the FDA Commissioner himself should it continue unchecked.

Pro-life Americans voted for leaders who promised to drain the swamp and govern with moral clarity. In the days ahead, hundreds of thousands will once again march in Washington to remind the nation that the fall of Roe v. Wade was not the end of the fight, but the beginning of a renewed commitment to defending life in law, medicine, and culture. Now it is time for leaders within the Trump administration to match that conviction with action and ensure that the institutions entrusted with protecting life truly honor the value of every human being.

LifeNews Note: Chad Connelly is the Founder & CEO of Faith Wins, an organization dedicated to helping faith leaders leverage their influence and impact within the governmental and political arena.

The post Life is Sacred. FDA Bureaucracy Is Not. Stop Abortion Pills Now appeared first on LifeNews.com.